New butyrate pill tested alongside statins for cholesterol control
NCT ID NCT06556745
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called BKR-017 in 9 adults already taking statins for high cholesterol. Researchers checked how the body handles BKR-017 and whether it builds up over a week of twice-daily dosing. The main goal was to see if it is safe and how it affects butyrate levels in the blood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
9 people
The number who actually took part.
- Started
-
Jul 2025
- Finished
-
Jun 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Healthy subjects on statin therapy between the ages of 18 and 70, inclusive.
- Ages
-
18 to 70 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Men and women, ages 18-70 inclusive * Subjects currently on statin treatments. Exclusion Criteria: * Presence of cirrhosis, or other causes of liver disease * Substantial alcohol consumption (\>20 g/day for women or \>30 g/day for men) * History of bariatric or intestinal surgery * Active gastrointestinal disease including but not limited to irritable bowel syndrome, inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis), diverticulitis, gastroparesis. * Active and clinically significant pancreatic disease, or renal disease as determined by the investigator. * History of heart disease that in the opinion of the investigator should exclude the subject from the study. * Untreated or uncontrolled hyperthyroidism or hypothyroidism, or other significant thyroid disease * Active significant infection as determined by the investigator. * Known allergy to butyrate or any of the components of the tablets. * Participation in a clinical trial and/or Dosing with an investigational drug during the 30 days before screening, or within 5 half-lives of receipt of an investigational drug or twice the duration of the biological effect of any investigational drug (whichever is longer) * Pregnant, nursing, or trying to become pregnant. * In the investigator's judgment, the subject is not suitable for the study for any other reason or cannot commit to the requirements of the study. * Taking part in another clinical trial or being in the exclusion period of a previous clinical trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hypercholesterolemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pennington Biomedical Research Center
Baton Rouge, Louisiana, 70808, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Once-Daily pill tame bad cholesterol?
- Can an unapproved device change how we manage this condition?
- Can a berberine supplement match red yeast rice for cholesterol?
- Bread that fights cholesterol? oat fiber put to the test
- Can a new pill tame high cholesterol?
- Ancient herbal mix put to the test against high cholesterol